CTLA4 and cancer: Recently, therapies using immune checkpoint inhibitors, such as anti-cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4), and the anti-programmed cell death protein 1 pathway (anti-PD-1/PD-L1) have performed well in the treatment of cancers.